Aoxing Pharmaceutical Company Inc.
AXN
AXN was delisted on the 16th of October, 2017.
11 hedge funds and large institutions have $147K invested in Aoxing Pharmaceutical Company Inc. in 2016 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 3 closing their positions.
21% less funds holding
Funds holding: 14 → 11 (-3)
44% less capital invested
Capital invested by funds: $262K → $147K (-$115K)
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$5.88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$75K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$22.7K |
| 3 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
-$17K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$6.71K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.47K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFA
1
BlackRock Fund Advisors
San Francisco,
California
| $61K | -$6.71K | -9,090 | -9% |
|
2
Bank of New York Mellon
New York
| $34K | -$2 | -3 | -0% |
|
|
3
Citadel Advisors
Miami,
Florida
| $17K | +$5.88K | +7,966 | +46% |
|
|
VKH
4
Virtu KCG Holdings
New York
| $11K | -$75K | -101,569 | -86% |
|
|
EWM
5
Evercore Wealth Management
New York
| $9K | – | – | – |
|
6
Creative Planning
Overland Park,
Kansas
| $7K | – | – | – |
|
|
BIM
7
BlackRock Investment Management
Wilmington,
Delaware
| $5K | – | – | – |
|
|
MA
8
MUFG Americas
New York
| $2K | -$1.83K | -2,480 | -41% |
|
|
9
UBS Group
Zurich,
Switzerland
| $1K | -$22.7K | -30,727 | -95% |
|
|
RCM
10
Rotella Capital Management
Bellevue,
Washington
| – | -$17K | -25,065 | Closed |
|
|
11
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$3.47K | -4,700 | -95% |
|
12
Citigroup
New York
| – | -$1K | -807 | Closed |
|
AXN Hedge Fund Activity: Q1 2016 in Review
11 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Aoxing Pharmaceutical Company Inc. (AXN) for Q1 2016, worth a combined $147K — down 44% from $262K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of AXN and 0 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 1 added.
The largest buyer was Citadel Advisors, adding an estimated $5.88K. The largest seller was Virtu KCG Holdings, cutting an estimated $75K.
- 11 institutional investors held Aoxing Pharmaceutical Company Inc. (AXN) as of Q1 2016, down from 14 in Q4 2015.
- Funds reported $147K of Aoxing Pharmaceutical Company Inc. stock for Q1 2016, down 44% quarter-over-quarter.
- 0 funds opened new Aoxing Pharmaceutical Company Inc. positions in Q1 2016 and 3 closed out, a net change of -3 holders.
- The largest Aoxing Pharmaceutical Company Inc. buyer in Q1 2016 was Citadel Advisors, an estimated $5.88K added.
- The largest Aoxing Pharmaceutical Company Inc. seller in Q1 2016 was Virtu KCG Holdings, an estimated $75K sold.
Based on aggregated 13F filings for Q1 2016.